Table 1.
Characteristics of study participants
| Characteristic | Total, n (%) | Gemcitabine + platinum (n=56), n (%) | Docetaxel + platinum (n=57), n (%) | P |
|---|---|---|---|---|
| Median age (years) | 51 (30-68) | 48.5 (30-68) | 54 (33-68) | 0.157 |
| Gender | ||||
| Male | 77 (68.1) | 39 (69.6) | 38 (66.7) | 0.734 |
| Female | 36 (31.9) | 17 (30.4) | 19 (33.3) | |
| Previous treatment | ||||
| IC + CCRT | 75 (66.4) | 33 (58.9) | 42 (73.7) | 0.424 |
| CCRT | 26 (23.0) | 16 (28.6) | 10 (17.5) | |
| CCRT + AC | 7 (6.2) | 4 (7.1) | 3 (5.3) | |
| IMRT | 5 (4.4) | 3 (5.4) | 2 (3.5) | |
| Time to disease progression (years) | ||||
| ≤1 | 40 (35.4) | 16 (28.6) | 24 (42.1) | 0.133 |
| >1 | 73 (64.6) | 40 (71.4) | 33 (57.9) | |
| ECOG score | ||||
| 0 | 6 (5.5) | 3 (5.4) | 3 (5.3) | 0.982 |
| 1 | 107 (94.5) | 53 (94.6) | 54 (94.7) | |
| Organ involved | ||||
| Liver | 8 (7.1) | 5 (8.9) | 3 (5.3) | 0.542 |
| Lung | 16 (14.2) | 9 (16.1) | 7 (12.3) | |
| Nonregional lymph nodes | 1 (0.9) | 1 (1.8) | 0 | |
| Multiple sites | 88 (77.8) | 41 (73.2) | 47 (82.4) | |
| Organ involvement | ||||
| Single organ | 24 (21.2) | 14 (25.0) | 10 (17.5) | 0.333 |
| Multiple organs | 89 (78.8) | 42 (75.0) | 47 (82.5) | |
| Liver metastasis | ||||
| Yes | 62 (54.9) | 29 (51.8) | 33 (57.9) | 0.514 |
| No | 51 (45.1) | 27 (48.2) | 24 (42.1) | |
| Lung metastasis | ||||
| Yes | 73 (64.6) | 34 (60.7) | 39 (68.4) | 0.392 |
| No | 40 (35.4) | 22 (39.3) | 18 (31.6) | |
| Platinum selection | ||||
| NDP | 96 (85.0) | 46 (82.1) | 50 (87.7) | 0.708 |
| DDP | 5 (4.4) | 3 (5.4) | 2 (3.5) | |
| CBP | 12 (10.6) | 7 (12.5) | 5 (8.8) |
IC – Induction chemotherapy; CCRT – Concurrent chemoradiotherapy; AC – Adjuvant chemotherapy; IMRT – Intensity modulated radiotherapy; NDP – Nedaplatin; DDP – Cisplatin; CBP – Carboplatin; ECOG – Eastern cooperative oncology group